As of 2025-09-16, the EV/EBITDA ratio of Kala Pharmaceuticals Inc (KALA) is -2.20. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KALA's latest enterprise value is 93.87 mil USD. KALA's TTM EBITDA according to its financial statements is -42.64 mil USD. Dividing these 2 quantities gives us the above KALA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2025-09-11 | -1.91 |
| 2025-09-10 | -1.69 |
| 2025-09-09 | -1.53 |
| 2025-09-08 | -1.59 |
| 2025-09-05 | -1.60 |
| 2025-09-04 | -1.59 |
| 2025-09-03 | -1.66 |
| 2025-09-02 | -1.29 |
| 2025-08-29 | -1.17 |
| 2025-08-28 | -1.09 |
| 2025-08-27 | -0.97 |
| 2025-08-26 | -0.92 |
| 2025-08-25 | -0.86 |
| 2025-08-22 | -0.91 |
| 2025-08-21 | -0.82 |
| 2025-08-20 | -0.80 |
| 2025-08-19 | -0.81 |
| 2025-08-18 | -0.83 |
| 2025-08-15 | -0.80 |
| 2025-08-14 | -0.76 |
| 2025-08-13 | -0.74 |
| 2025-08-12 | -0.68 |
| 2025-08-11 | -0.65 |
| 2025-08-08 | -0.68 |
| 2025-08-07 | -0.65 |
| 2025-08-06 | -0.67 |
| 2025-08-05 | -0.72 |
| 2025-08-04 | -0.69 |
| 2025-08-01 | -0.69 |
| 2025-07-31 | -0.60 |
| 2025-07-30 | -0.65 |
| 2025-07-29 | -0.81 |
| 2025-07-28 | -0.75 |
| 2025-07-25 | -0.77 |
| 2025-07-24 | -0.63 |
| 2025-07-23 | -0.45 |
| 2025-07-22 | -0.43 |
| 2025-07-21 | -0.46 |
| 2025-07-18 | -0.47 |
| 2025-07-17 | -0.50 |
| 2025-07-16 | -0.49 |
| 2025-07-15 | -0.43 |
| 2025-07-14 | -0.46 |
| 2025-07-11 | -0.48 |
| 2025-07-10 | -0.61 |
| 2025-07-09 | -0.54 |
| 2025-07-08 | -0.39 |
| 2025-07-07 | -0.41 |
| 2025-07-03 | -0.38 |
| 2025-07-02 | -0.38 |